ADU

Congrats to Biogen for not giving up on this therapy and advancing the care for patients. Remarkable day - incredible data!

 

Now we know why Ehlers left, he couldn't stomach the fraud.
"At first pass the results still appear to be marginal, with inconsistent treatment effects between the two studies and for different endpoints, but the critical question will be what reassurance the company has received from the FDA. This could range from “the agency has reviewed all the data with us and has guaranteed approval” to “you can file whatever you want and we’ll review it”. Unfortunately investors will not be privy to where between those two extremes the agency-company interactions have been. Regardless, this filing will now come down to a torturous discussion of data, statistics, endpoints, exposure, treatment effects and safety liabilities. It will probably NOT include a discussion of the massive societal and economic cost of going further down this rabbit-hole of marginal treatment effects in such a widespread and catastrophic disease." J. Porges

 

I would be VERY surprised if the FDA approved this without mandating another confirmatory Phase III.

 

CEO is an unethical man. Ehlers knew every piece of this data, yet ran for the hills weeks prior? Come on. Total scam going on here. Investors are so stupid, and so are all of you employees for staying at the most miserable culture in Cambridge. Best of luck to you all! This drug NEVER sees a CVS or Walgreens.

JOKE on human lives. Welcome to the NEW Biogen.

 

it is curious, why would ehlers leave now?

 

Or Ehlers went from an EVP at Biogen to CEO of Limelight Bio. Sometimes people actually leave jobs for better opportunities.

That or he left in protest against the Biogen deep state cabal of nefarious ne'er-do-wells. Whichever makes more sense to you I guess.

 

No way he would miss out on the opportunity to be the first R&D head in 40 years to bring a new AD therapy to market. He left because he refused to drink the coolaid.

 

No way he would miss out on the opportunity to be the first R&D head in 40 years to bring a new AD therapy to market. He left because he refused to drink the coolaid.

 

he left because him and his R&D team made a mistake

 

Do you want to try ONE more time to respond after three tries? Get over yourself and realize this may actually work for patients. With you in every aspect of the company but lets at least TRY to get behind this new data!!!

 

Let’s see what the FDA says.